Key points from article :
Angitia Biopharmaceuticals, a clinical-stage biotechnology company headquartered in Woodland Hills, California, has raised $120 million in a Series C funding round to advance its pipeline of therapies targeting serious musculoskeletal diseases, with a particular focus on osteoporosis. Osteoporosis is a common and debilitating condition characterized by reduced bone mass and structural deterioration, affecting more than 200 million people globally. It is especially prevalent among postmenopausal women and ageing populations, representing a significant and growing public health challenge. Angitia aims to address this unmet medical need through innovative approaches to bone health.
The company’s lead candidate, AGA2118, is a bispecific antibody that simultaneously inhibits sclerostin and DKK1, two proteins that negatively regulate WNT signalling, a pathway crucial for bone metabolism and the activity of osteoblasts (bone-building cells). This dual-targeting strategy is designed to enhance bone mineral density (BMD) by preventing compensatory increases in either protein, a common limitation of therapies targeting only one pathway. AGA2118 is currently being evaluated in the ARTEMIS Phase 2 clinical trial, which recently dosed its first patient. The study focuses on postmenopausal women at high risk of fractures, aiming to enrol 350 participants and assess changes in lumbar spine BMD after 12 months.
Angitia’s pipeline extends beyond osteoporosis, with additional drug candidates in development, including AGA2115 for osteogenesis imperfecta, a genetic condition that causes brittle bones, and AGA111 for spinal fusion. The recent $120 million funding round was led by Bain Capital Life Sciences, with participation from prominent investors such as Janus Henderson, OrbiMed, and Legend Capital. This significant financial support reflects strong investor confidence in Angitia’s innovative therapeutics and strategic vision.
